VEA
MIRM icon

Virtus ETF Advisers’s Mirum Pharmaceuticals MIRM Stock Holding History

Virtus ETF Advisers’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Buy
4,100
+100
+3% +$10K 0.18% 143
2026
Q1 		$370K Hold
4,000
– – 0.17% 152
2025
Q4 		$316K Hold
4,000
– – 0.15% 162
2025
Q3 		$293K Buy
+4,000
New +$254K 0.16% 167
2025
Q1 		– Sell
-8,270
Closed -$342K – 640
2024
Q4 		$342K Sell
8,270
-4,074
-33% -$170K 0.14% 211
2024
Q3 		$481K Hold
12,344
– – 0.23% 183
2024
Q2 		$422K Buy
12,344
+1,329
+12% +$34.8K 0.21% 183
2024
Q1 		$277K Buy
11,015
+1,585
+17% +$43.6K 0.15% 229
2023
Q4 		$278K Sell
9,430
-1,309
-12% -$39.6K 0.18% 229
2023
Q3 		$339K Sell
10,739
-1,390
-11% -$38.1K 0.21% 193
2023
Q2 		$314K Sell
12,129
-4,960
-29% -$132K 0.19% 193
2023
Q1 		$410K Buy
17,089
+299
+2% +$6.82K 0.23% 145
2022
Q4 		$327K Buy
16,790
+4,472
+36% +$88.4K 0.17% 235
2022
Q3 		$259K Buy
12,318
+181
+1% +$4.36K 0.1% 286
2022
Q2 		$236K Buy
12,137
+976
+9% +$23K 0.09% 308
2022
Q1 		$246K Sell
11,161
-656
-6% -$13.4K 0.11% 186
2021
Q4 		$188K Sell
11,817
-167
-1% -$2.6K 0.07% 234
2021
Q3 		$239K Sell
11,984
-618
-5% -$10.1K 0.11% 224
2021
Q2 		$218K Buy
12,602
+87
+0.7% +$1.56K 0.09% 284
2021
Q1 		$248K Buy
12,515
+223
+2% +$4.27K 0.1% 290
2020
Q4 		$215K Sell
12,292
-5,166
-30% -$102K 0.09% 338
2020
Q3 		$336K Sell
17,458
-2,377
-12% -$51K 0.18% 200
2020
Q2 		$386K Buy
+19,835
New +$331K 0.18% 214

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtus ETF Advisers's MIRM Position: Q2 2026 in Review

Virtus ETF Advisers increased its Mirum Pharmaceuticals (MIRM) stake by 2.5% in Q2 2026, buying an estimated $10K and bringing the position to 4,100 shares worth $480K. The position accounts for 0.18% of the portfolio, ranked #143.

Virtus ETF Advisers first reported a position in MIRM in Q2 2020 and has held it in 23 quarters since. The position peaked at $481K in Q3 2024. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Virtus ETF Advisers held 4,100 shares of Mirum Pharmaceuticals worth $480K as of Q2 2026.
  • Virtus ETF Advisers bought 100 Mirum Pharmaceuticals shares in Q2 2026, an estimated $10K.
  • Mirum Pharmaceuticals made up 0.18% of Virtus ETF Advisers's portfolio in Q2 2026, its #143 holding.
  • Virtus ETF Advisers first reported a position in Mirum Pharmaceuticals in Q2 2020 and has held it in 23 quarters since.
  • Virtus ETF Advisers's Mirum Pharmaceuticals position peaked at $481K in Q3 2024.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.